# A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

> **NCT00225550** · PHASE1,PHASE2 · TERMINATED · sponsor: **Adherex Technologies, Inc.**

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** ADH -1 (Exherin™)

## Key facts

- **NCT ID:** NCT00225550
- **Lead sponsor:** Adherex Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2007-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225550, "A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00225550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*